Martin Zenni is a Cardiology physician affiliated with University of Florida. OpenAlex indexes 106 publications with 2,416 citations (h-index 22).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
655 W 8th St
Ufjp Cardiology Dept
Jacksonville, FL 32209
Telephone
904-244-3378Registry record last updated 12 Jun 2018.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Shockwave Medical, IncProgram year20253 payments
- Edwards Lifesciences CorporationProgram year20251 payment
- ABIOMEDProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
85.7%Statin21%Atorvastatin Calcium75%Rosuvastatin Calcium17%Pravastatin Sodium4%Simvastatin4%Part D<11 patientsBeta blocker18.2%Metoprolol Succinate50%Carvedilol28%Metoprolol Tartrate12%Atenolol6%Bisoprolol Fumarate5%Part D<11 patients+ 11 more classes in this area
Blood & clotting
12.4%P2Y12 inhibitor9.1%Clopidogrel81%Prasugrel Hcl19%Part D<11 patientsFactor Xa inhibitor3.3%Eliquis100%Part D<11 patientsMetabolism & gastrointestinal
1.9%Potassium supplement1.9%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- P2Y12 Inhibition in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention
JACC: Cardiovascular Interventions
2024 - Clopidogrel-Mediated P2Y12 Inhibition According to Renal Function in Patients With Diabetes Mellitus and CAD
JACC Basic to Translational Science
2024 - IMPACT OF RACE ON PLATELET REACTIVITY PROFILES IN PATIENTS ON CLOPIDOGREL TREATMENT
Journal of the American College of Cardiology
2024 - Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention
JACC: Cardiovascular Interventions
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Steven Dekosky, MD
University of Florida
Peter Draganov, MD
University of Florida
Irene Malaty, MD
University of Florida
David Winchester, MD
University of Florida
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”